Evidence map›Paper›PMID 41408399›Full record

ArticleCommunications biology2025

Non-redundant roles of the phosphoinositide phosphatases PTEN and PIPP in PI3K/AKT signaling in breast cancer.

Lisa M Ooms, Daniel T Ferguson, Samuel J Rodgers, Karmanpreet K Sukhija, Emily I Jones, Mariah P Csolle, Hon Yan Kelvin Yip, Roger J Daly, Tony Tiganis, Catriona A McLean and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Lisa M Ooms *Cancer Program, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC, Australia.ORCID http://orcid.org/0000-0002-8918-9932
Daniel T Ferguson *Cancer Program, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC, Australia.
Samuel J RodgersCancer Program, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC, Australia.ORCID http://orcid.org/0000-0002-7186-8355
Karmanpreet K SukhijaCancer Program, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC, Australia.
Emily I JonesCancer Program, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC, Australia.
Mariah P CsolleCancer Program, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC, Australia.
Hon Yan Kelvin YipCancer Program, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC, Australia.ORCID http://orcid.org/0000-0002-6281-6852
Roger J DalyCancer Program, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC, Australia.ORCID http://orcid.org/0000-0002-5739-8027
Tony TiganisCancer Program, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC, Australia.ORCID http://orcid.org/0000-0002-8065-9942
Catriona A McLeanDepartment of Anatomical Pathology, Alfred Hospital, Prahran, VIC, Australia.ORCID http://orcid.org/0000-0002-0302-5727
Antonella PapaCancer Program, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC, Australia.ORCID http://orcid.org/0000-0001-8653-7121
Christina A MitchellCancer Program, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC, Australia. christina.mitchell@monash.edu.ORCID http://orcid.org/0000-0001-9372-3192

Funding

Department of Health | National Health and Medical Research Council (NHMRC) APP1121472
6 · The paper itself

Abstract

Phosphoinositide 3-kinase (PI3K) signaling is hyperactivated in ~70% of breast cancers via mutations in oncogenes including PIK3CA or inactivation/depletion of phosphoinositide (PI)-phosphatases. Generation of PI(3,4,5)P

Indexed as

Breast NeoplasmsPhosphatidylinositol 3-KinasesPhosphoinositide PhosphatasesPhosphoric Monoester HydrolasesProto-Oncogene Proteins c-aktPTEN PhosphohydrolaseSignal TransductionAnimalsCell Line, TumorFemaleHumansMicephosphatidylinositol-3,4-bisphosphate 4-phosphatasePhosphatidylinositol 3-KinasesPhosphoinositide PhosphatasesPhosphoric Monoester HydrolasesProto-Oncogene Proteins c-aktPTEN PhosphohydrolasePTEN protein, humanPten protein, mouse

Identifiers

PMID41408399
PMCPMC12827249

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.